Undisclosed Enhanced Antibody Program
HER2-positive breast cancer
Key Facts
About Score Pharma
Score Pharma is a private, pre-revenue biotechnology company developing next-generation, ADCC-enhanced antibody therapeutics for oncology. Its core innovation is a proprietary process technology designed to modify existing, clinically-validated antibodies to increase their potency and improve patient response, aiming to radically de-risk and shorten the traditional drug development timeline. The company initially targets HER2-positive breast cancer, melanoma, renal cell carcinoma, and colorectal cancer. Operating with a virtual model based in Alabama, it relies on strategic partnerships and external resources to advance its pipeline.
View full company profileAbout Score Pharma
Score Pharma is a private, pre-revenue biotechnology company developing next-generation, ADCC-enhanced antibody therapeutics for oncology. Its core innovation is a proprietary process technology designed to modify existing, clinically-validated antibodies to increase their potency and improve patient response, aiming to radically de-risk and shorten the traditional drug development timeline. The company initially targets HER2-positive breast cancer, melanoma, renal cell carcinoma, and colorectal cancer. Operating with a virtual model based in Alabama, it relies on strategic partnerships and external resources to advance its pipeline.
View full company profileAbout Score Pharma
Score Pharma is a private, pre-revenue biotechnology company developing next-generation, ADCC-enhanced antibody therapeutics for oncology. Its core innovation is a proprietary process technology designed to modify existing, clinically-validated antibodies to increase their potency and improve patient response, aiming to radically de-risk and shorten the traditional drug development timeline. The company initially targets HER2-positive breast cancer, melanoma, renal cell carcinoma, and colorectal cancer. Operating with a virtual model based in Alabama, it relies on strategic partnerships and external resources to advance its pipeline.
View full company profileAbout Score Pharma
Score Pharma is a private, pre-revenue biotechnology company developing next-generation, ADCC-enhanced antibody therapeutics for oncology. Its core innovation is a proprietary process technology designed to modify existing, clinically-validated antibodies to increase their potency and improve patient response, aiming to radically de-risk and shorten the traditional drug development timeline. The company initially targets HER2-positive breast cancer, melanoma, renal cell carcinoma, and colorectal cancer. Operating with a virtual model based in Alabama, it relies on strategic partnerships and external resources to advance its pipeline.
View full company profileTherapeutic Areas
Other HER2-positive breast cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Anbenitamab (KN026) | AlphaMab Oncology | Phase 3 |
| Membrex™ | Metaclipse Therapeutics | Pre-clinical |
| HER2DX® | Reveal Genomics | Commercial |
| HER2+ cVLP Vaccine | AdaptVac | Phase 1 |
| NERLYNX® (neratinib) | Specialized Therapeutics | Commercial |